Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLIANT THERAPEUTICS, INC.

(PLRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
11.53(c) 11.2(c) 10.73(c) 11.39(c) 11.5(c) Last
93 448 49 881 120 937 121 085 94 763 Volume
-1.54% -2.86% -4.20% +6.15% +0.97% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7,72 M - -
Net income 2021 -101 M - -
Net cash position 2021 186 M - -
P/E ratio 2021 -4,10x
Yield 2021 -
Sales 2022 3,56 M - -
Net income 2022 -125 M - -
Net cash position 2022 283 M - -
P/E ratio 2022 -3,55x
Yield 2022 -
Capitalization 414 M 414 M -
EV / Sales 2021 29,6x
EV / Sales 2022 36,9x
Nbr of Employees 90
Free-Float -
More Financials
Company
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-├č). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of av├č6 and av├č1.... 
Sector
Pharmaceuticals
Calendar
03/15Earnings Release
More about the company
Ratings of Pliant Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about PLIANT THERAPEUTICS, INC.
01/11Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expec..
AQ
01/11Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expec..
CI
01/10PLIANT THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/06Adverum Biotechnologies Names Star Seyedkazemi Chief Development Officer
MT
2021Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021Pliant Therapeutics Shares Higher After Oppenheimer Starts Coverage
MT
2021Oppenheimer Initiates Coverage on Pliant Therapeutics With Outperform Rating, $40 Price..
MT
2021Pliant Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Star..
MT
2021Pliant Therapeutics to Participate in Upcoming Investor Conferences
GL
2021Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial ..
PU
2021PLIANT THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021PLIANT THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
2021Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
2021Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial ..
AQ
2021HC Wainwright Starts Pliant Therapeutics at Buy With $45 Price Target
MT
More news
News in other languages on PLIANT THERAPEUTICS, INC.
01/11Pliant Therapeutics souligne les développements récents du programme principal Pln-7480..
01/06Adverum Biotechnologies nomme Star Seyedkazemi au poste de directeur du développement.
2021Les actions de Pliant Therapeutics sont en hausse après qu'Oppenheimer ait commencé à l..
2021Pliant Therapeutics publie les résultats préliminaires positifs d'un essai clinique pou..
2021Pliant Therapeutics enregistre une perte et une baisse des revenus au quatrième trimest..
More news
Analyst Recommendations on PLIANT THERAPEUTICS, INC.
More recommendations
Chart PLIANT THERAPEUTICS, INC.
Duration : Period :
Pliant Therapeutics, Inc. Technical Analysis Chart | PLRX | US7291391057 | MarketScreener
Technical analysis trends PLIANT THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 11,50 $
Average target price 46,17 $
Spread / Average Target 301%
EPS Revisions
Managers and Directors
Bernard Coulie President, Chief Executive Officer & Director
Keith Lamont Cummings Chief Financial Officer
Ho Young Huh Lead Director
Eric Lefebvre Chief Medical Officer
Gregory P. Cosgrove Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
PLIANT THERAPEUTICS, INC.-14.81%414
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963